Slc31a2 belongs to the solute carrier family 31 (SLC31) of copper transporters. Key functional insights include:
Copper Homeostasis: Facilitates low-affinity copper uptake and mobilizes intracellular copper stores from endosomes/lysosomes .
Regulatory Role: Modulates SLC31A1 (CTR1) activity by stabilizing its truncated form, influencing copper and cisplatin accumulation .
Localization: Primarily resides in intracellular membranes (e.g., late endosomes, lysosomes) rather than the plasma membrane .
Studies in mice reveal that Slc31a2 expression decreases under copper supplementation, suggesting feedback regulation .
Recombinant Slc31a2 is produced using E. coli expression systems, ensuring high yield and purity . Validation methods include:
Western Blot: Detected in mouse pancreas using anti-Slc31a2 polyclonal antibodies (e.g., CAB16362) .
ELISA: Quantifiable in tissue homogenates with a sensitivity range of 0.156–10 ng/ml .
Functional Assays: Demonstrated copper transport activity in vitro, albeit with lower affinity compared to CTR1 .
Copper-Related Disorders: Used to study Menkes disease and Wilson’s disease, where copper metabolism is disrupted .
Cancer Research: Linked to cisplatin resistance; knockdown enhances cisplatin uptake in cancer cells .
Subcellular Trafficking: Localization studies using immunofluorescence reveal its role in vesicular copper release .
Gene Expression Analysis: RT-qPCR profiles show tissue-specific expression, with high levels in the liver and kidney .